Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancerresults of the EORTC 08912 phase I/II study

European Journal of Cancer

Volumn 36, Issue 5, 2000, Pages 592-600

  Uitterhoeve, A L J ^a   Belderbos, J S A ^b   Koolen, M G J ^a   Van Der Vaart, P J M ^b   Rodrigus, P T R ^c   Benraadt, J ^d   Koning, C C M ^e   Gonzalez Gonzalez D ^a   Bartelink, H ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

^d Integraal Kankercentrum Amsterdam   (Netherlands)

^e MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

cDDP; Concurrent radiochemotherapy; Conformal radiotherapy; NSCLC

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DOSIMETRY; ESOPHAGITIS; ESOPHAGUS; FEMALE; HUMAN; LEUKOPENIA; LUNG FUNCTION TEST; LUNG NON SMALL CELL CANCER; MALE; MONITORING; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RECURRENT DISEASE; THROMBOCYTOPENIA; TREATMENT PLANNING; TUMOR VOLUME; VITAL CAPACITY; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY; SURVIVAL ANALYSIS; TIME FACTORS; VITAL CAPACITY;

EID: 0034012998     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00315-9     Document Type: Article

References (44)

1. Janssen Heynen M. Trends in Lung Cancer Incidence and Survival. Academic thesis. Enschede, PrintPartners Ipskamp, 1998.
2. Parkin DM, Whelan SL, Ferlay J, et al. In Parkin DM, Whelan SL, Ferlay J, eds. Cancer Incidence in Five Continents, Vol. VII. Lyon, IARC Scientific Publications No 143, 1997.
3. Dosoretz D.E., Katin M.J., Blizter P.H.et al. Medically inoperable lung carcinoma. the role of radiation therapy Semin. Radiat. Oncol. 6:1996;98-104.
4. Perez C.A., Pajak T.F., Rubin P.et al. Long term observations in the pattern of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer. 59:1987;1874-1881.
5. Arriagada R., Le Chevalier T., Quoix E.et al. Effect of chemotherapy on locally advanced non-small cell lung carcinoma. a randomized study of 353 patients Int. J. Radiat. Oncol. Biol. Phys. 20:1991;1183-1190.
6. Cox J.D., Azarnia N., Byhardt R.W.et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 to 79.2 Gy: possible survival benefit with 69.9 Gy in favourable patients with stage III non-small cell lung carcinoma. report of the Radiation Therapy Oncology Group 83-11 J. Clin. Oncol. 8:1990;1543-1555.
7. Graham M.V. Phase I/II study of treatment of locally advanced (T3/T4) non-oatcell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 82-12). long term results Int. J. Radiat. Oncol. Biol. Phys. 31:1995;819-825.
8. King S. High dose accelerated hyperfractionated radiotherapy using a concurrent boost for the treatment of non-small cell lung cancer. unusual toxicity and promising results Int. J. Radiat. Oncol. Biol. Phys. 28:1996;593-599.
9. Schaake-Koning C., Schuster-Uitterhoeve A., Hart G., Gonzälez González D. Prognostic factors of inoperable localized lung cancer treated by high dose radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 9:1983;1023-1028.
10. Saunders M.I., Dische S., Barett A.et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer. a randomized multicenter trial Lancet. 350:1997;161-165.
11. Jeremic B. Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non-small cell lung cancer. a randomized study J. Clin. Oncol. 14:1996;1065-1070.
12. Schaake-Koning C., v.d. Bogaert W., Dalesio O.et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N. Engl. J. Med. 326:1992;524-530.
13. Byhardt R.W., Scott C., Sause W.T.et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;469-478.
14. Komaki R., Scott C.B., Sause W.T.et al. Induction cisplatin/vinblastin and irradiation vs irradiation in unresectable squamous cell lung cancer. failure patterns by cell type in RTOG 88-08/ECOG 4588 Int. J. Radiat. Oncol. Biol. Phys. 39:1997;537-544.
15. Komaki R., Scott C., Ettinger D.et al. Randomized study of chemotherapy/radiation therapy combinations for favourable patients with locally advanced inoperable non-small cell lung cancer. Radiation Therapy Oncology Group (RTOG) 92-04 Int. J. Rad. Biol. Oncol. Phys. 38:1997;149-155.
16. Perez C.A., Stanley K., Hansen W.et al. Impact of irradiated technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Cancer. 50:1982;1059-1091.
17. Robertson J.M., R ten Haken R.K., Hazuka M.B.et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;1079-1085.
18. Martel M.K., Strawderman M., Hazuka M.B.et al. Volume and dose parameters for survival of non-small cell lung cancer patients. Radiother. Oncol. 44:1997;23-29.
19. Graham MV, Purdy JA, Harms W, et al. Survival and prognostic factors of non-small cell lung cancer patients treated with definitive three-dimensional radiation therapy. Int J Radiat Oncol Biol Phys 1998, 42(Suppl.), 166 (abstract).
20. Fu X.L., Jiang G-L., Wang L-J.et al. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer. clinical phase I/II trial Int. J. Radiat. Oncol. Biol. Phys. 39:1997;545-552.
21. Cox J.D. Interruptions of high-dose radiation therapy decreases long term survival of favourable patients with unresectable non-small cell carcinoma of the lung. analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials Int. J. Radiat. Oncol. Biol. Phys. 27:1993;493-498.
22. Schuster-Uitterhoeve A.L.J., v d Vaart P.J.M., Schaake-Koning C.C.E.et al. Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer. Eur. J. Cancer. 32A:1996;1314-1319.
23. Jeremic J., Shibamoto Y., Stanisavljevic B.et al. Radiation alone or with concurrent low-dose either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck. a prospective randomized trial Radiother. Oncol. 43:1997;29-37.
24. Morris M., Eifel P., Lu J.et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and papa-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 40:1999;1137-1143.
25. Keys H., Bundy B.N., Stehman F.B.et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 340:1999;1154-1161.
26. Rose P.G., Bundy B.N., Watkins E.B.et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340:1999;1144-1153.
27. Merlano M., Vitale V., Rosso R.et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N. Engl. J. Med. 327:1992;1115-1121.
28. Brizel D.M., Albers M.E., Fisher S.R.et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 338:1998;1798-1804.
29. Trovo M.G., Minatel E., Franchin G.et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 24:1992;11-15.
30. Bedini A.V., Tacecchio L., Milani F.et al. Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma. Cancer. 67:1991;357-362.
31. Le Pechoux C., Arriagada R., Le Chevalier T.et al. Concurrent cisplatin-vindesine and hyperfractionated thoracic radiotherapy in locally advanced non-small cell lung cancer. Int. J. Radiat. Biol. Oncol. Phys. 35:1996;519-525.
32. Armstrong J., Raben A., Zelefski M.et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother. Oncol. 44:1997;17-22.
33. Kelly K., Hazuka M., Pan Z.et al. A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 40:1998;559-567.
34. Bardet E., Riviere A., Charloux A.et al. A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced non-small cell lung cancer. final analysis Int. J. Radiat. Oncol. Biol. Phys. 38:1997;163-168.
35. Yamada M., Kudoh K., Hirata K., Nakajima T., Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur. J. Cancer. 34:1998;71-75.
36. Graham M.V. Predicting radiation response. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;561-562.
37. Ten Haken R.K., Martel M.K., Kessler M.L.et al. Use of Veff and iso-NTCP in the implementation of dose escalation protocols. Int. J. Radiat. Biol. Oncol. Phys. 27:1993;689-695.
38. Kwa S.S.L., Theuws J.C.M., Wagenaar A.et al. Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis. Radiother. Oncol. 48:1998;61-69.
39. Segawa Y., Takigawa N., Kataoka M.et al. Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;91-98.
40. Emami B., Lyman J., Brown A.et al. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 21:1991;109-122.
41. Chemotherapy in non-small cell lung cancer. a meta-analysis using updated data on individual patients from 52 randomised clinical trials Br. Med. J. 311:1995;899-909.
42. Dillman R.O., Herndon J., Seagren S.L.et al. Improved survival in stage III non-small cell lung cancer. seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial J. Natl. Cancer Inst. 88:1996;1210-1215.
43. Sause W.T., Scott C., Taylor S.et al. Radiation Therapy Oncology Group (RTOG) 8808 and Eastern Cooperative Oncology Group (ECOG) 4588. Preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer J. Natl. Cancer Inst. 87:1995;198-205.
44. Van Zandwijk N. Phase II study of gemcitabin plus cisplatin as induction regimen for patients with stage IIIA non-small cell lung cancer by the EORTC Lung Cancer Cooperative Group (EORTC 08955). Proc. ASCO. 17:1998;468a.